PQR-309 is primarily used in the field of oncology as a potent and selective inhibitor of PI3K and mTOR pathways, which are critical in cancer cell growth and survival. Its application is focused on targeting solid tumors and hematologic malignancies, making it a promising candidate for cancer therapy. Clinical trials have explored its efficacy in treating advanced cancers, particularly those resistant to conventional treatments. Additionally, PQR-309 is being investigated for its potential to enhance the effectiveness of other anticancer therapies when used in combination. Its ability to penetrate the blood-brain barrier also opens possibilities for treating brain tumors and central nervous system-related cancers.